Showing 4251-4260 of 10505 results for "".
- Phase 3 Study: Aclaris Therapeutics’ A-101 45% May Help Thwart Common Wartshttps://practicaldermatology.com/news/phase-3-study-aclaris-therapeutics-a-101-45-may-help-thwart-common-warts/2460198/Aclaris Therapeutics, Inc.’s A-101 45% Topical Solution (A-101 45%), an investigational new drug, for the potential treatment of common warts, performed well in its second Phase 3 clinical trial, THWART-1 (WART-301). A-101 45% met the primary and all secondary efficacy endpoints,
- Positive Top-line Results Seen in Pivotal Phase 3 Clinical Trial of StrataGraft Regenerative Tissue Deep Partial-thickness Thermal Burnshttps://practicaldermatology.com/news/positive-top-line-results-seen-in-pivotal-phase-3-clinical-trial-of-stratagraft-regenerative-tissue-deep-partial-thickness-thermal-burns/2460178/Mallinckrodt plc's pivotal Phase 3 clinical trial evaluating the efficacy and safety of a single application of StrataGraft regenerative tissue in the treatment of deep partial-thickness thermal burns met both primary endpoints. The pivotal open-label, controlled, randomized, multic
- Soliton Treats First Patients in Cellulite Trialhttps://practicaldermatology.com/news/soliton-treats-first-patients-in-cellulite-trial/2460124/The first patients in Soliton’s cellulite trial have been treated, the Company reports. "Patient treatments have now begun at the Chicago site,” says Dr. Chris Capelli, President, CEO and co-founder of Soliton, in a ne
- Positive Top-Line Results Seen in Study of Crisaborole for Mild to Moderate AD in Young Childrenhttps://practicaldermatology.com/news/positive-top-line-results-seen-in-study-of-crisaborole-of-for-mild-to-moderate-ad-in-young-children/2460085/Pfizer’s crisaborole ointment (Eucrisa) was well-tolerated in children aged 3 months to less than 24 months with mild to moderate atopic dermatitis (AD), according to top-line results from a Phase 4 study (CrisADe CARE 1). The data from the trial are supportive of the primary stud
- Kamedis: Clinical Study Validates Traditional Chinese Botanical for Eczemahttps://practicaldermatology.com/news/kamedis-clinical-study-validates-traditional-chinese-botanical-for-eczema/2460020/Traditional Chinese botanicals in homeopathic over-the-counter Kamedis Calm Eczema Therapy Cream play a pivotal role in the product’s ability to reduce eczema rashes, according to results of a new study announced by the company. Results show that commer
- Xstrahl Introduces UpGraded Treatment System for Non-Melanoma Skin Cancerhttps://practicaldermatology.com/news/xstrahl-introduces-upgraded-treatment-system-for-non-melanoma-skin-cancer/2460011/Xstrahl Medical is launching its latest superficial radiotherapy treatment system to treat the full range of non-melanoma skin cancer cases. The new Xstrahl 150 system offers several features that enhance the capabilities of Xstrahl's curr
- La Roche-Posay to Sponsor a Patient to Visit Thermal Dermatology Center: Accepting Nominationshttps://practicaldermatology.com/news/la-roche-posay-to-sponsor-a-patient-to-visit-thermal-dermatology-center-accepting-nominations/2459995/La Roche-Posay brand is sponsoring a patient to travel to the Thermal Dermatology center in the town of La Roche-Posay, France this fall. With 8,000 visitors per year, a third of whom are children, the La Roche-Posay thermal center is Europe’s leading thermal dermatology center for sensitiv
- Bimekizumab Provides Long-Term Skin Clearance for Psoriasis Patients in Phase 2b Studyhttps://practicaldermatology.com/news/ucbs-bimekizumab-performs-well-in-extension-study/2459873/UCB’s bimekizumab demonstrated long-term maintenance of complete or almost complete skin disease resolution for psoriasis patients, according to results from the Phase 2b BE ABLE 2 Extension Study presented at the 2019 American Academy of Dermatology Annual Meeting (AAD) in Washington,
- Hoth Therapeutics Names Dr. Adam Friedman to Scientific Advisory Boardhttps://practicaldermatology.com/news/hoth-therapeutics-names-dr-adam-friedman-to-scientific-advisory-board/2459887/Hoth Therapeutics, Inc. has named Adam Friedman, MD to the Company's Scientific Advisory Board. Hoth is a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis. The Scientific Adviso
- Industry Vet Todd Zavodnick Joins Dermavent Sciences as CEOhttps://practicaldermatology.com/news/industry-vet-todd-zavodnick-joins-dermavent-sciences-as-ceo/2457506/Todd Zavodnick is the new Chief Executive Officer of Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences. "It is an honor to join Dermavant at such an exciting time in the company's growth," says Mr. Zavodnick in a news release. "Medical dermatology